Secukinumab Provides Sustained Improvements in Clinical and Imaging Outcomes in Patients with Psoriatic Arthritis and Axial Manifestations: Results from the MAXIMISE Trial Xenofon Baraliakos, MD – Rheumazentrum Ruhrgebiet Herne
3:10 PM – 3:20 PM ET
Maintenance or Achievement of Minimal Disease Activity Following Therapy Optimization with Adalimumab or Methotrexate in Patients with Psoriatic Arthritis: Results from Part 2 of a Randomized, Open-Label Phase 4 Study Philip J. Mease, MD – Seattle Rheumatology Associates
3:20 PM – 3:30 PM ET
Comparison of Secukinumab versus Adalimumab Efficacy by Sex in Psoriatic Arthritis from a Phase 3b, Double-blinded, Randomized, Active-controlled Study Grace C. Wright, MD, PhD, FACR – Grace C Wright MD PC
3:30 PM – 3:40 PM ET
Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19-Subunit of Interleukin-23, Through Week 52 of a Phase 3, Randomized, Double-blind, Placebo-controlled Study Conducted in Biologic-naïve Patients with Active Psoriatic Arthritis Iain B. McInnes, FRCP – University of Glasgow
3:40 PM – 3:50 PM ET
Efficacy and Safety of Upadacitinib in Patients with Active Psoriatic Arthritis and Inadequate Response to Biologic Disease-Modifying Anti-Rheumatic Drugs: A Double-Blind, Randomized Controlled Phase 3 Trial Philip J. Mease, MD – Seattle Rheumatology Associates
